EGLN1 and breast cancer: By contrast, studies from a spontaneously arising PyMT-oncogene-driven breast cancer model showed that inhibition of PHD2 significantly decreased the number of metastases in the lung, supporting the pro-oncogenic role of PHD2 in breast cancer [25].